Pharmaceutical Technology

MARCH 10, 2023

In Lebanon, the battle for access to medicines rages on and is further heightened by dramatic decreases to the healthcare budget last year. GlobalData reviews the key events leading up to these current price trends in Lebanon. This is a price jump of an additional 887% compared to between 2017–21.

Insurance 52

Insurance Packaging 52

Pharmaceutical Technology

FEBRUARY 10, 2023

Partly in response to such drugs, risk-sharing agreements (RSAs) have increased in popularity and aim to mitigate the risks of including high-cost drugs on reimbursement lists and healthcare plans. GlobalData takes this opportunity to review the various types of RSAs and their evolution over time.

FDA 105

FDA 105

Pharmaceutical Technology

OCTOBER 5, 2022

Technology is advancing the possibilities of healthcare treatments, from the development of innovative new drugs to freeing up time for doctors thanks to monitoring devices for patients with conditions such as diabetes and high blood pressure. between 2017 and 2021, peaking at 453 deals in 2020, according to GlobalData figures.

Compounding 52

Compounding 52

Pharmaceutical Technology

OCTOBER 26, 2022

According to GlobalData insight, gene therapies are expected to display the greatest forecasted sales growth, with an increase over 1,200%, while gene-modified cell therapies are expected to show the second greatest forecasted sales growth, with an increase slightly below 1,000%. The future of cell and gene therapies.

FDA 52

FDA Immunization 52

Pharmaceutical Technology

AUGUST 8, 2022

In 2017, the US Food and Drug Administration (FDA) broke ground by approving the first drug with an embedded biosensor to track its use. There’s no dearth of interest, however, in applying digital solutions to healthcare. GlobalData is the parent company of Pharmaceutical Technology.

FDA 122

FDA Hospitals 122

pharmaphorum

SEPTEMBER 16, 2022

Despite the RSV vaccine threat, analysts at GlobalData have predicted that nirsevimab could reach $3 billion in annual revenue by 2030, assuming a launch next year. Its closest rival GSK suffered a setback when it was forced to abandon phase 3 trials of its candidate on safety grounds earlier this year.

Vaccines 59

Vaccines Immunization 59

Pharmaceutical Technology

MAY 3, 2023

“According to the FDA, the introduction of generic medicines offers patients “same as brand” drugs at 39% lower-than-average price,” says Surbhi Gupta, an industry analyst within Frost & Sullivan’s healthcare and life sciences practice area. Evaluate the effects of COVID-19 on the sector.

FDA 98

FDA Generic Medicine Communication 98